Excalibur To Test AZ Compound In Diabetics With COVID-19
Potential Benefits Include Reduced Incidence Of ARDS
A randomized double-blind study will look at whether a glucokinase activator in addition to usual care can help improve clinical outcomes in type 1 and 2 diabetes patients with coronavirus symptoms.
You may also be interested in...
The European Commission is in talks to buy vaccines from CureVac and Moderna, amid concerns over “vaccine nationalism” and lack of transparency. Meanwhile the EU health technology assessment network has begun publishing “rolling collaborative reviews” of potential COVID-19 therapies, and two more firms have announced progress with monoclonal antibodies.
Under EU rules, once a medicinal product has been placed on the market in a country of the EEA – the EU plus Iceland, Liechtenstein and Norway
The EU pharmaceutical strategy published on 25 November will be the first step in a “complete overhaul” of the medicines legislative framework to be proposed in about two years’ time, says the European Commission.